MASLD and cardiovascular risk explained

A 2026 review in Current Hypertension Reports makes a point that gets lost in most coverage of fatty liver drugs. The thing most likely to kill someone with metabolic dysfunction-associated steatotic liver disease (MASLD) is not their liver. It is their heart. MASLD affects 38% of adults globally, and cardiovascular disease is the leading cause of death across every stage of the condition^[1]. That is the frame worth holding when you read about semaglutide and MASH.

Liver fibrosis predicts cardiac events

The review's headline finding is prognostic rather than therapeutic. Fibrosis stage is the strongest independent predictor of cardiovascular outcomes in MASLD, conferring up to a 2.5-fold increase in events beyond traditional risk factors^[1]. Noninvasive tools carry part of that signal too. Fibrosis-4 (FIB-4, a score built from age, two liver enzymes and platelet count) and liver stiffness measurement both predict cardiovascular mortality^[1].

The practical gap follows from that. Fibrosis-based risk stratification remains absent from standard cardiovascular risk models^[1]. A patient can score unremarkably on a conventional risk calculator and still carry liver-derived risk the calculator was never built to see. The authors treat this as the argument for reading MASLD as a systemic cardiometabolic condition rather than a hepatology problem parked in a separate clinic.

Where semaglutide enters

The review names semaglutide and resmetirom as the two drugs currently offering benefits on both sides of the ledger, hepatic and cardiometabolic^[1]. Resmetirom is a thyroid hormone receptor beta agonist and sits outside this site's remit. Semaglutide is a GLP-1 receptor agonist with large randomised data on both endpoints, which is what makes it the interesting case.

On the liver side, the ESSENCE phase 3 trial randomised 1,197 patients with biopsy-defined MASH and fibrosis stage 2 or 3 to once-weekly subcutaneous semaglutide 2.4 mg or placebo. The planned interim analysis of the first 800 patients at week 72 reported resolution of steatohepatitis without worsening of fibrosis in 62.9% of the semaglutide group against 34.3% of the placebo group, and a reduction in fibrosis without worsening of steatohepatitis in 36.8% against 22.4%^[2]. Mean body-weight change was minus 10.5% with semaglutide and minus 2.0% with placebo^[2].

On the cardiovascular side, SELECT enrolled 17,604 patients aged 45 or older with preexisting cardiovascular disease and a body-mass index of 27 or above, but no history of diabetes. Over a mean 39.8 months of follow-up, the composite of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke occurred in 6.5% on semaglutide 2.4 mg and 8.0% on placebo, a hazard ratio of 0.80^[3].

Two trials that never met

Same molecule, same weekly dose, and still no answer to the question the review poses. SELECT did not enrol on liver criteria, so how many of those 17,604 patients had MASLD, and at what fibrosis stage, is not something the trial can tell you. ESSENCE's endpoints are histological. Its part 2 runs to week 240 with cirrhosis-free survival as the primary outcome and an estimated completion date of April 2029, which is still a liver endpoint rather than a cardiac one^[4]. The dose in both trials was the 2.4 mg weekly presentation.

The review states the limitation plainly. Therapies with combined liver and cardiovascular benefits are promising, but whether improving liver disease reduces cardiovascular events remains uncertain^[1]. That is a causal claim nobody has tested. A 10% drop in body weight moves a lot of cardiovascular risk factors on its own, and separating a liver-mediated effect from a weight-mediated one needs a trial designed to do it.

The labels have not joined them either

The US Wegovy prescribing information now carries both indications: reducing the risk of major adverse cardiovascular events, and treating noncirrhotic MASH with moderate to advanced liver fibrosis. The MASH indication was granted under accelerated approval based on improvement of MASH and fibrosis, with continued approval contingent on verification of clinical benefit in a confirmatory trial^[5]. The US regulatory picture tracks that split.

The EU separated them further still. Semaglutide for MASH is authorised as a distinct brand, Kayshild, under a conditional marketing authorisation dated 26 March 2026, for adults with non-cirrhotic MASH and fibrosis stages F2 to F3. That indication says nothing about cardiovascular outcomes^[6]. Two regulators, two frameworks, and neither claims the liver benefit buys a cardiac one. The European picture differs by country on reimbursement, not on that basic point.

What we don't yet know

Three gaps stand out. Whether treating MASLD lowers cardiovascular events, which no completed trial was designed to answer. Whether FIB-4 or liver stiffness should change cardiovascular treatment decisions rather than simply flag risk. And how much of semaglutide's effect in either organ is weight loss doing the work. Tirzepatide is being studied in the same disease area, and the cardiovascular question there is just as open.

Semaglutide is a prescription-only medicine across every jurisdiction we cover, and MASLD is diagnosed and staged in clinic rather than from a symptom checklist. If you are reading this because a scan flagged a fatty liver, the useful next step is a conversation about fibrosis staging and cardiovascular risk together, with someone who can order both. Country-by-country status sits on the semaglutide regulation section and the UK regulation hub, with the US hub covering the compounding and telehealth routes.